Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Opioids Could Lower Suicide Risk, Suggests Early Study

By Drug Discovery Trends Editor | February 9, 2016

Results from a preliminary trial suggests low doses of a common painkiller could help treat emotional pain as well as physical.

A research team from Washington State University worked in conjunction with scientists from the University of Haifa in Israel to conduct an experiment to see how an opioid called buprenorphine could counter suicidal feelings, writes The New Scientist.

Low doses of buprenorphine were given to a test group of 40 patients identified as high risk for suicide while a psychiatrist monitored the volunteers’ emotions weekly using a questionnaire for a month period. Placebos were given to another 20 patients.

Here’s how the results broke down. The average score of the questionnaire was 20, which as New Scientist explains “is deemed worrying enough to hospitalize a person for their own safety.”

Patients given the opioid saw their score go down six points after one week and nearly 10 points by the experiment’s conclusion. The placebo group saw their scores dip two points. Twelve members taking the drug were unable to participate in the full trial, and two patients (one from each group) tried to commit suicide during the experiment.

Volunteers who completed the full treatment period reported that their condition did not worsen.

Popular Science adds buprenorphine “didn’t inhibit the efficacy of other forms of treatment,” like antidepressants. More research needs to be done to determine which patients should take these painkillers for treating suicidal thoughts as well as to understand the safest dosing since these drugs have addictive qualities.

The study was published in the American Journal of Psychiatry.


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE